EVENTS
2025/12/10
2026年1月21日(水)13:00-16:30AIプレシジョンPDXZセミナー
2025/12/09
Cuvier duct PDXZ の 実験的転移アッセイ (Experimental Metastasis Assay)
2025/12/08
PDXZにおける腫瘍増殖抑制試験 (Tumor Growth Inhibition)
2025/12/02
2026年1月21日(水)13:00-16:30PDXZネットセミナー
2025/11/25
2025/11/25
2025/11/17
ZMDD2025 第11回ゼブラフィッシュ・メダカ創薬研究会
2025/10/07
AIプレシジョン患者がん移植ゼブラフィッシュシステムのプロトコル開発
2025/09/05
2025/06/16
discovery of stanniocalcin1 as cardiotoxic defence gene
2024/04/25
We have discovered stanniocalcin1 as cardiotoxic defence gene in 2015. the potential clinical applications of stanniocalcin in oncocardiology include its use as a biomarker for cancer therapy-induced cardiotoxicity, its potential as a therapeutic target for cardioprotection, and its role in regulating calcium homeostasis, which may be relevant for managing calcium-related cardiovascular complications in cancer patients.
